NASDAQ:VCYT
Veracyte Stock News
$20.97
-0.82 (-3.76%)
At Close: Jun 14, 2024
Veracyte Commends New USPSTF Lung Cancer Screening Guidelines
05:15pm, Wednesday, 10'th Mar 2021
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte Commends New USPSTF Lung Cancer Screening Guidelines
Veracyte: Not Too Excited After Momentum Run
06:42am, Monday, 01'st Mar 2021
Veracyte has a huge momentum run in 2021 thanks to accelerating operating and stock market momentum. I like the secular growth potential, yet fear that investors have gotten a bit too enthusiastic.
Veracyte, Inc. (VCYT) CEO Bonnie Anderson on Q4 2020 Results - Earnings Call Transcript
11:41pm, Wednesday, 17'th Feb 2021
Veracyte, Inc. (VCYT) CEO Bonnie Anderson on Q4 2020 Results - Earnings Call Transcript
Veracyte (VCYT) Reports Q4 Loss, Tops Revenue Estimates
06:11pm, Wednesday, 17'th Feb 2021
Veracyte (VCYT) delivered earnings and revenue surprises of -55.56% and 0.02%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Veracyte: Q4 Earnings Insights
04:25pm, Wednesday, 17'th Feb 2021
Shares of Veracyte (NASDAQ:VCYT) were unchanged in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share were up 6.67% over the past year to ($0.14), which m
Veracyte Raises $550M In Upsized Equity Offering For Decipher Biosciences Acquisition
05:54am, Friday, 05'th Feb 2021
Veracyte Inc (NASDAQ: VCYT) has priced an upsized underwritten public offering of around 7.4 million common shares at $74 per share, with gross proceeds of approximately $550 million. Earlier, the
Veracyte Announces Pricing of Upsized Public Offering of 7,432,433 Shares of Common Stock
10:45pm, Thursday, 04'th Feb 2021
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte Announces Pricing of Upsized Public Offering of 7,432,433 Shares of Common Stock
Veracyte Announces Proposed Public Offering of Common Stock
04:32pm, Wednesday, 03'rd Feb 2021
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) (the “Company”) today announced that it has commenced an underwritten public offering of $400.0 million in shares of its
Veracyte to Acquire Decipher Biosciences
07:05am, Wednesday, 03'rd Feb 2021
SOUTH SAN FRANCISCO, Calif., & SAN DIEGO, Calif.--(BUSINESS WIRE)--Veracyte To Acquire Decipher Biosciences
Veracyte to Participate in 23rd Annual Needham Virtual Growth Conference
02:00pm, Wednesday, 06'th Jan 2021
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte to Participate in 23rd Annual Needham Virtual Growth Conference
Veracyte (VCYT) in Focus: Stock Moves 7% Higher
09:47am, Tuesday, 22'nd Dec 2020
Veracyte (VCYT) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.
Bayer and Veracyte Announce Precision Oncology Collaboration in Thyroid Cancer
08:15am, Tuesday, 22'nd Dec 2020
WHIPPANY, N.J. & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Bayer and Veracyte (Nasdaq:VCYT) today announced a new collaboration to advance the Precision Oncology Patient Identification Program in
Veracyte: A Strong Recovery Turning Into Strong Growth In The Midst Of A Pandemic
10:18pm, Monday, 21'st Dec 2020
Veracyte: A Strong Recovery Turning Into Strong Growth In The Midst Of A Pandemic
Veracyte to Host Virtual Lung Cancer R&D Day on Wednesday, December 16, 2020
02:30pm, Thursday, 03'rd Dec 2020
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte to Host Virtual Lung Cancer R&D Day on Wednesday, December 16, 2020
Veracyte, Inc. (VCYT) CEO Bonnie Anderson on Q3 2020 Results - Earnings Call Transcript
11:33pm, Monday, 02'nd Nov 2020
Veracyte, Inc. (VCYT) CEO Bonnie Anderson on Q3 2020 Results - Earnings Call Transcript
